Identifying New Strategies to Optimize the Management and Treatment of COPDMannino, David M.Journal of Managed Care Medicine
*This is not a complete list of medications used for chronic obstructive pulmonary disease (COPD). † This is the only formulation of this specific combination of drugs approved by the Food and Drug Administration for tre...
A gap exists between guidelines and real-world clinical practice for the management and treatment of chronic obstructive pulmonary disease (COPD). Although this has narrowed in the last decade, there is room for improvement in detection rates, treatment choices and disease monitoring. In practical te...
the progressive decline of pulmonary function, the real goals of COPD management are: prevention (e. g. stop smoking), early diagnosis, and treatment ... M Zamparella,P Scalera,F Anelli 被引量: 0发表: 2017年 加载更多来源期刊 Australian family physician 2010/03/01 研究点推荐 COPD Chronic...
Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematical... JD Campbell,DSD Ramsey - 《Pharmacoeconomics》 被引量: 125发表: 2009年 A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Mainte...
You breathe fast and hard, even when taking medicines. Takeaways COPD makes it hard for you to breathe and tends to get worse over time. But there are lots of things you can do to slow it down and feel better. Work with your doctor to come up with a management plan that gives you...
19. Global Initiative for Asthma. Global strategy for asthma management and prevention. https://ginasthma.org/gina-reports/ Date last updated: 2022. 20. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian SevereAsthma Registry (BSAR). Respi...
[2]Martin A, Badrick E, Mathur R, et al. Effect ofethnicity on the prevalence, severity, and management of COPD in general practice. Br J Gen Pract 2012;62(595):e76- 81 [3]Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian pati...
and long-acting beta(2)-adrenoceptor agonist single-inhaler combination for both maintenanceand rescue therapy:A paradigm shift in asthma management. Treat... DAD D’Urzo - 《Treatments in Respiratory Medicine》 被引量: 54发表: 2006年 Clinical Safety of Long-Acting β 2 -Agonist and Inhaled Co...
Other differences include the role for nebulizers and metered-dose inhalers, secretion clearance methodologies, and the treatment of acute COPD exacerbations and acute respiratory failure. All three guidelines agree that more research is needed to improve our understanding and management of COPD. 展开 ...